Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates
Regulators Also Highlight Need To Preserve Supplies For Non-COVID-19 Uses
Executive Summary
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.
You may also be interested in...
EU Platform Trials Project Piques WHO’s Interest
The World Health Organization is developing a new best practice guideline on improving the quality and efficiency of clinical trials and is keen to learn what role platform trials can play on this front and their acceptability by the clinical trial community.
WHO Member States Agree To Strengthen Global Clinical Trial Ecosystem
World Health Assembly delegates have given the thumbs up to a resolution that draws on lessons learnt during the COVID-19 pandemic to improve global coordination on how clinical trials are designed, evaluated and reported.
WHO Member States Agree To Strengthen Global Clinical Trial Ecosystem
World Health Assembly delegates have given the thumbs up to a resolution that draws on lessons learnt during the COVID-19 pandemic to improve global coordination on how clinical trials are designed, evaluated and reported.